The Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet)

Last updated: February 22, 2023
Sponsor: Seoul St. Mary's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Polyps

Colon Polyps

Treatment

N/A

Clinical Study ID

NCT05737017
Coajet_LGI
  • Ages 18-85
  • All Genders

Study Summary

The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure. In this study, the investigators examine the hemostatic effect of ClearCoajet on intraprocedural bleeding during endoscopic mucosal resection or endoscopic submucosal dissection for colorectal sessile polyps or lateral growth tumors larger than 1.5 cm. The investigators also aim to compare the delayed bleeding and recurrence rates between the ClearCoajet group and the control group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patients with colorectal sessile polyps or lateral growth tumors larger than 1.5 cm

Exclusion

Exclusion Criteria:

  • Pedunculated polyp
  • Patients with coagulopathy

Study Design

Total Participants: 400
Study Start date:
November 01, 2022
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Yeouido St. Mary's Hospital

    Seoul, 07345
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.